Angiogenesis Inhibitors and Hypertension: An Emerging Issue

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · see citing works

A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer

Yang, J. C., Haworth, L. R., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,681 · see citing works

Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer

Miller, K. D., Chap, L. I., Holmes, F. A., Cobleigh, M., Marcom, P. K., Fehrenbacher, L., Dickler, M. N., Overmoyer, B. A., Reimann, J. D., Sing, A. P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.098 · Cited by 1,303 · see citing works

The VIVA Trial

Henry, T. D., Annex, B. H., McKendall, G. R., Azrin, M., López, J. J., Giordano, F. J., Shah, P. K., Willerson, J. T., Benza, R. L., Berman, D. S., et al. (2003) · Circulation · doi:10.1161/01.cir.0000061911.47710.8a · Cited by 1,025 · see citing works

Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors

Strumberg, D., Richly, H., Hilger, R. A., Schleucher, N., Korfee, S., Tewes, M., Faghih, M., Brendel, E., Voliotis, D., Haase, C. G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.124 · Cited by 872 · see citing works

VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells

Hood, J. D., Meininger, C. J., Ziche, M., & Granger, H. J. (1998) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1998.274.3.h1054 · Cited by 696 · see citing works

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease

Fiedler, W., Serve, H. L., Döhner, H., et al. (2005) · Blood · doi:10.1182/blood-2004-05-1846 · Cited by 495 · see citing works

Safety and Pharmacokinetics of the Dual Action Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor, BAY 43-9006, in Patients with Advanced, Refractory Solid Tumors

Clark, J. W., Eder, J. P., Ryan, D. P., Lathia, C. D., & Lenz, H. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2658 · Cited by 340 · see citing works

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

Awada, A. H., Hendlisz, A., Gil, T., Bartholomeus, S., Mano, M. S., de Valeriola, D. L., Strumberg, D., Brendel, E., Haase, C. G., Schwartz, B. E., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602584 · Cited by 334 · see citing works

Mechanisms of Hypertension Associated With BAY 43-9006

Veronese, M. L., Mosenkis, A., Flaherty, K. T., Gallagher, M., Stevenson, J. P., Townsend, R. R., & O'Dwyer, P. J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.0503 · Cited by 324 · see citing works

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors

Moore, M. J., Hirte, H. W., Siu, L. L., Oza, A. M., Hotte, S. J., Petrenciuc, O., Cihon, F., Lathia, C. D., & Schwartz, B. E. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi310 · Cited by 303 · see citing works

Apoptosis Induced by the Kinase Inhibitor BAY 43-9006 in Human Leukemia Cells Involves Down-regulation of Mcl-1 through Inhibition of Translation

Rahmani, M., Davis, E. M., Bauer, C., Dent, P., & Grant, S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506551200 · Cited by 286 · see citing works

Manipulating angiogenesis in medicine

Carmeliet, P. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2003.01297.x · Cited by 208 · see citing works

Angiogenic growth factors and hypertension

Sane, D. C., Anton, L., & Brosnihan, K. B. (2004) · Angiogenesis · doi:10.1007/s10456-004-2699-3 · Cited by 197 · see citing works

Therapeutic angiogenesis and vasculogenesis for tissue regeneration

Madeddu, P. R. (2005) · Experimental Physiology · doi:10.1113/expphysiol.2004.028571 · Cited by 184 · see citing works

Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584

THOMAS, A., Morgan, B., Drevs, J., Unger, C., Wiedenmann, B. J., Vanhoefer, U. J., Laurent, D., Dugan, M. H., & Steward, W. P. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)70023-2 · Cited by 97 · see citing works

New Chemotherapeutic Advances in Pancreatic, Colorectal, and Gastric Cancers

Díaz‐Rubio, E. (2004) · The Oncologist · doi:10.1634/theoncologist.9-3-282 · Cited by 81 · see citing works

Update on angiogenesis inhibitors

Zakarija, A., & Soff, G. A. (2005) · Current Opinion in Oncology · doi:10.1097/01.cco.0000183672.15133.ab · Cited by 80 · see citing works

Hypertension and Angiogenesis

Kiefer, F. W., Neysari, S., Humar, R., et al. (2003) · Current Pharmaceutical Design · doi:10.2174/1381612033454540 · Cited by 72 · see citing works

High blood pressure. A side effect of drugs, poisons, and food

Grossman, E. (1995) · Archives of Internal Medicine · doi:10.1001/archinte.155.5.450 · Cited by 70 · see citing works

Modifications structurelles et fonctionnelles de la microcirculation dans l???hypertension

Agabiti‐Rosei, E. (2003) · Drugs · doi:10.2165/00003495-200363991-00003 · Cited by 36 · see citing works

High Blood Pressure

Grossman, E. (1995) · Archives of Internal Medicine · doi:10.1001/archinte.1995.00430050022003 · Cited by 35 · see citing works

[Structural and functional changes of the microcirculation in hypertension: influence of pharmacological therapy].

Agabiti‐Rosei, E. (2003) · PubMed · Cited by 34 · see citing works

The structural basis of hypertension: vascular remodelling, rarefaction and angiogenesis/arteriogenesis

Bobik, A. (2005) · Journal of Hypertension · doi:10.1097/01.hjh.0000174970.56965.4f · Cited by 34 · see citing works

Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association

Carey, R. M., Calhoun, D. A., Bakris, G. L., Brook, R. D., Daugherty, S. L., Dennison-Himmelfarb, C. R., Egan, B. M., Flack, J. M., Gidding, S. S., Judd, E., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000084 · Cited by 1,153 · see citing works

Intracranial hemorrhage in patients treated with bevacizumab：Report of two cases

Takeshi, Nishimura, Makoto, M., et al. (2011) · Acta Scientiarum Naturalium Universitatis Sunyatseni

Bevacizumab 5 or 7.5 mg/kg in Metastatic Colorectal Cancer Can Be Infused Safely Over 10 Minutes

Mahfoud, T., Tanz, R., Mesmoudi, M., et al. (2011) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-010-9245-x · Cited by 5 · see citing works

Bevacizumab Can Be Infused Safely Over 10 Minutes in Metastatic Colorectal Cancer

Mahfoud, T., & Réda, K. M. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu165.178

Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer

Lee, Chun, ○., Park, et al. (2012) · Acta Scientiarum Naturalium Universitatis Sunyatseni · Cited by 5 · see citing works

Two Cases of Leg Ulcer Caused by Bevacizumab

Jinnai, S., SUENAGA, A., Murata, M., et al. (2017) · The Nishinihon Journal of Dermatology · doi:10.2336/nishinihonhifu.79.468 · Cited by 1 · see citing works